Halozyme, Oruka Partner on Psoriasis Drug Technology
Halozyme Therapeutics and Oruka Therapeutics have entered into a global exclusive collaboration and licensing agreement focused on advancing innovative drug delivery technology for inflammatory diseases, including psoriasis.
Under the agreement, Halozyme’s wholly owned subsidiary, Halozyme Hypercon, Inc., will grant Oruka access to its proprietary Hypercon™ technology platform for use with ORKA-001, Oruka’s investigational therapy currently being developed for psoriasis and related inflammatory disorders. The deal also includes rights for use with up to one additional therapeutic target.
Hypercon™ is a microparticle-based drug delivery technology designed to enable the hyperconcentration of biologics and other medicines. By allowing higher concentrations of drugs in smaller injection volumes, the technology aims to improve patient convenience and support easier administration of injectable therapies. Industry experts believe such approaches could become increasingly important as biologic medicines continue to dominate treatment strategies for chronic immune-mediated diseases.
The collaboration marks Halozyme’s second Hypercon-related partnership announced this year and reflects growing pharmaceutical interest in technologies that can improve the delivery profile of biologic therapies.
Helen Torley said the agreement demonstrates increasing validation of the Hypercon platform across multiple therapeutic applications.
“We are pleased to announce our second Hypercon collaboration this year, further validating the broad applicability and partner interest in this technology,” Torley said. “We look forward to advancing Hypercon with Oruka’s innovative biologics that are designed to deliver meaningful freedom from chronic disease for patients.”
Oruka Therapeutics is developing biologic therapies aimed at improving treatment outcomes for patients with chronic skin diseases, including psoriasis. The company believes integrating Hypercon technology into ORKA-001 may help optimize dosing and administration while potentially improving the overall patient experience.
Lawrence Klein said the partnership aligns with the company’s strategy of developing differentiated therapies for chronic inflammatory conditions.
“We are excited to partner with Halozyme’s Hypercon in our pursuit to offer the best possible medicines to people with chronic skin conditions like psoriasis,” Klein said. “We look forward to applying the full potential of this technology to our product candidates to further enhance the profile we can deliver to patients over time.”
Financial details of the agreement include an upfront payment from Oruka to Halozyme, along with potential milestone payments tied to development and commercialization achievements. Halozyme will also be eligible to receive mid-single-digit royalties on future net sales of products developed using the Hypercon™ platform.
The partnership reflects broader trends within the biotechnology sector, where companies are increasingly focusing not only on therapeutic effectiveness but also on improving drug delivery methods that can reduce treatment burden and increase patient adherence.